- Conditions
- Clostridium Difficile Associated Disease
- Interventions
- C. difficile vaccine, C. difficile vaccine +adjuvant
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Pembroke Pines, Florida • South Miami, Florida • Overland Park, Kansas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1177–1200
of 4,214
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Insulin Resistance
- Interventions
- Liraglutide, Sugar Pill
- Drug
- Lead sponsor
- Phoenix VA Health Care System
- Federal
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Idiopathic Inflammatory Myositis
- Interventions
- Daxdilimab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Healthy
- Interventions
- granisetron
- Drug
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Parkinson's Disease
- Interventions
- LY3962681, Placebo (aCSF)
- Drug · Other
- Lead sponsor
- Prevail Therapeutics
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 7
- States / cities
- Englewood, Colorado • New Haven, Connecticut • Naples, Florida + 4 more
- Conditions
- Osteoarthritis
- Interventions
- Placebo saline injection, Ropivicaine 0.5%
- Other · Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Osteoarthritis
- Interventions
- Canakinumab, Placebo to canakinumab, Naproxen, Placebo to Naproxen
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 8
- States / cities
- Anniston, Alabama • Mesa, Arizona • San Diego, California + 5 more
- Conditions
- Overweight and Obesity, Healthy
- Interventions
- NG101, Placebo, Semaglutide Injectable Product
- Drug
- Lead sponsor
- Neurogastrx, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Meniere's Disease
- Interventions
- OTO-104, Placebo
- Drug
- Lead sponsor
- Otonomy, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Asthma
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Herpes Simplex Virus
- Interventions
- Novel Antiviral Drug, Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 1 Day to 98 Days
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 15 more
- Conditions
- SARS-CoV-2 Infection
- Interventions
- 25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
- Biological · Drug
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Systemic Juvenile Idiopathic Arthritis
- Interventions
- Canakinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 19 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Acthar, Placebo
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more
- Conditions
- Peripheral Arterial Disease
- Interventions
- Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months., Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.
- Drug · Other
- Lead sponsor
- Leonardo Clavijo
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Sepsis
- Interventions
- Glutamine, Placebo
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 72 Hours
- Enrollment
- 1,433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 12 more
- Conditions
- Human Immunodeficiency Virus (HIV) Infection
- Interventions
- HB-502 and HB-501 alternating 2-vector therapy Dose Level 1, HB-502 and HB-501 alternating 2-vector therapy Dose Level 2, Placebo
- Biological · Other
- Lead sponsor
- Hookipa Biotech GmbH
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Decatur, Georgia • Boston, Massachusetts + 1 more
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal, Headache
- Interventions
- Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone, Placebo Pteryogpalatine Fossa Injection
- Drug · Procedure
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Gainesville, Florida • Miami, Florida • Stuart, Florida + 10 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Etanercept, Methotrexate, Placebo
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Psoriasis
- Interventions
- Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 837 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 26
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 23 more
- Conditions
- Substance Use Disorders, Methamphetamine Abuse, Methamphetamine Intoxication
- Interventions
- CS-1103, Sterile Saline
- Drug
- Lead sponsor
- Clear Scientific, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Interventions
- Angiotensin 1-7, Saline solution
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Tucson, Arizona
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Tulisokibart, Placebo, Methotrexate
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • Mesa, Arizona • La Palma, California + 13 more
- Conditions
- Cat Allergy, Cat Hypersensitivity
- Interventions
- AMG 157, Cat Immunotherapy, Cat Immunotherapy Placebo, AMG 157 Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more